3 US Penny Stocks With Market Caps Over $300M To Watch

In This Article:

The U.S. stock market recently faced a downturn as concerns over China's advancements in artificial intelligence technology weighed heavily on major indices, particularly affecting the tech sector. For investors seeking opportunities beyond large-cap stocks, penny stocks—though an older term—still hold potential for growth and value. These typically smaller or newer companies can offer affordability and growth potential when backed by strong financials, making them worth watching amidst fluctuating market conditions.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

QuantaSing Group (NasdaqGM:QSG)

$3.08

$128.29M

★★★★★★

BAB (OTCPK:BABB)

$0.86

$6.22M

★★★★★★

Kiora Pharmaceuticals (NasdaqCM:KPRX)

$3.80

$11.49M

★★★★★★

Inter & Co (NasdaqGS:INTR)

$4.97

$2.18B

★★★★☆☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.2874

$10.58M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.48

$49.83M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$3.03

$60.21M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.30

$23.41M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8893

$80.06M

★★★★★☆

Click here to see the full list of 713 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

OmniAb

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: OmniAb, Inc. is a biotechnology company focused on the discovery and provision of therapeutic antibody discovery technologies in the United States, with a market cap of approximately $387.24 million.

Operations: The company generates revenue primarily through its Research Services segment, totaling $20.41 million.

Market Cap: $387.24M

OmniAb, Inc., a biotechnology firm, is navigating challenges typical of penny stocks, with recent financials showing a decline in revenue to US$4.17 million for the third quarter of 2024 and increasing net losses. Despite being unprofitable and not expected to turn profitable in the near future, OmniAb benefits from having no debt and sufficient cash runway for over a year based on current free cash flow. The management team is experienced with an average tenure of 2.2 years, though insider selling has been significant recently. Revenue growth is projected at 26.88% annually despite ongoing challenges.

NasdaqGM:OABI Debt to Equity History and Analysis as at Jan 2025
NasdaqGM:OABI Debt to Equity History and Analysis as at Jan 2025

GoodRx Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: GoodRx Holdings, Inc. provides consumers in the United States with tools to compare prescription drug prices and save on purchases, with a market cap of approximately $1.90 billion.